AI-Powered Regulatory Submissions

-

AI-Powered Regulatory Submissions: A New Era for IND, NDA, & BLA Documentation 

Drug development has always relied heavily on regulatory submissions. Regulatory documentation has changed over time, moving from paper-based dossiers to the widely used electronic Common Technical Document (eCTD). Even eCTD procedures, often managed with traditional RIMS Software (Regulatory Information Management Systems), are displaying their limitations, though, as life sciences organizations struggle with growing data volumes, intricate international regulatory requirements such as those handled by Regulatory Services in UK, and pressure to speed time-to-market.

Regulatory Submissions

The Current Regulatory Submission Landscape

To understand the impact of AI, it’s crucial to grasp the scope of traditional eCTD regulatory submissions: 

 

  • IND: Required to initiate clinical trials in humans. Involves detailed data on preclinical studies, CMC (chemistry, manufacturing, and controls), and the trial protocol. 

  • NDA: Seeks approval for marketing small molecule drugs. Requires robust evidence on safety, efficacy, and quality, often including multiple modules and study reports. 

  • BLA: Similar to NDA but specific to biologic products (e.g., monoclonal antibodies, vaccines, gene therapies). 

Artificial intelligence (AI) is revolutionizing the development, compilation, review, and submission of Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) dossiers as we enter a new era of AI-powered submissions.

Read the Full blog, to know more : https://resource.ddregpharma.com/blogs/ai-powered-regulatory-submissions-a-new-era-for-ind-nda-bla-documentation/

Follow us on :

Facebook: https://www.facebook.com/DDReg/

LinkedIn: https://www.linkedin.com/company/ddregpharma

Twitter: https://x.com/DDRegPharma

Instagram: https://www.instagram.com/ddregpharma

Comments

Post a Comment

Popular posts from this blog

What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development

-
Image
What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development An Investigational Medicinal Product Dossier (IMPD) is a key document in the clinical trial and drug development process, specifically for drugs or biologics undergoing testing in human clinical trials within the European Union (EU). It serves as a comprehensive report detailing the quality, manufacture, and control of the investigational product. The IMPD is a crucial regulatory submission required by the European Medicines Agency (EMA) or national regulatory bodies to evaluate whether a clinical trial can proceed. Key Components of an IMPD The IMPD includes several sections, providing information that ensures the safety and efficacy of the investigational product. These sections typically cover: Product Description and Composition: The IMPD provides detailed information about the investigational product, including its chemical composition, formulation, and dosage forms. Manufacturing and Control: This...
Read more

GMP Compliance in the Era of Advanced Therapies and Biologics

-
Image
Navigating the New Frontier: GMP Compliance for ATMPs and Biologics The global biopharmaceutical industry is undergoing a transformative shift as Advanced Therapy Medicinal Products (ATMPs)—including gene therapies, somatic cell therapies, and tissue-engineered products—and complex biologics become central to innovation pipelines. With over 1,900 active CGT clinical trials globally as of Q2 2025, according to a report by ARM, these living therapies offer unprecedented clinical benefits. However, their unique nature presents a significant challenge: traditional Good Manufacturing Practice (GMP) frameworks, designed for stable, small molecule drugs, are often not directly applicable. Their development, manufacturing, and distribution demand a fundamentally different approach to compliance. often requiring specialized GMP compliance services . The GMP Paradigm Shift for Living Products What makes ATMPs and biologics so unique from a GMP perspective? Living Products with Inherent Variabili...
Read more

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea

-
Image
Navigating Quasi-Drug Regulations and Market Entry in Japan and South Korea In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals . Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial landscape of quasi drugs in these two key markets is essential for global companies aiming to enter or expand in East Asia. This article explores the updated guidelines, approval requirements, and commercialization opportunities for quasi drugs in Japan and South Korea.  What Are Quasi Drugs? Quasi drugs are defined as products that have mild pharmacological effects or physiological functions. They may not be as potent as traditional drugs, but they go beyond the scope of general cosmetics. Th...
Read more